Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Merck & Co.'s new HIV protease inhibitors

Jan. 22, 1998

HIV protease inhibitor research continues at DuPont Merck

Jan. 21, 1998

New HIV vaccine from VaxGen cleared for phase I/II studies

Jan. 20, 1998

Provir set to enter final stage of development for AIDS-related diarrhea

Jan. 19, 1998

Peptide HIV protease inhibitors claimed by Merck & Co.

Jan. 19, 1998

Anti-HIV therapy with adefovir may also prevent the development of Kaposi's sarcoma

Jan. 16, 1998

Further mechanism of action studies described for AMD-3100

Jan. 16, 1998

Unimed submits NDA for AIDS-related illness

Jan. 16, 1998

Novel AIDS Rx technology available for licensing from NIH

Jan. 16, 1998

Three new AIDS vaccine trials examine novel approaches

Jan. 15, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...